Dr. Halmos on Trastuzumab Deruxtecan in NSCLC

Publication
Video
Supplements and Featured PublicationsUtilizing Antibody-Drug Conjugates and Other Novel Agents in Lung Cancer
Volume 1
Issue 1

Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.

Balazs Halmos, MD, professor, medical oncology, Department of Oncology, professor, oncology and hematology, Department of Medicine, chief, thoracic oncology, Albert Einstein College of Medicine, Montefiore Medical Center, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer (NSCLC), and how fam-trastuzumab deruxtecan-nxki (Enhertu) meets needs for patients with HER2-mutant disease.

The NSCLC treatment landscape is introducing an effective new class of agents, antibody-drug conjugates, Halmos says. For example, trastuzumab deruxtecan is FDA approved in the molecularly selected subset of patients with HER2-mutant NSCLC, Halmos notes.

The agent demonstrated excellent efficacy and durable responses in the phase 2 DESTINY-Lung02 trial (NCT04644237), in which it elicited a confirmed overall response rate of 58%, Halmos explains. Testing for HER2 in patients with NSCLC is crucial, as trastuzumab deruxtecan is an effective addition to the armamentarium for patients with this mutation, Halmos concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,